PULM - Pulmatrix, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Lexington,
United States
Type: Equity
PULM price evolution
PULM
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $13.8 | $16.3 | $19.17 | |
| Short term investments | ||||
| Net receivables | $0.02 | $0.64 | $0.57 | $0.93 |
| Inventory | ||||
| Total current assets | $11.45 | $15.64 | $17.58 | $20.84 |
| Long term investments | $0.05 | $1.47 | $1.47 | |
| Property, plant & equipment | $11.2 | $11.47 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.14 | $12.81 | $13.12 | |
| Total investments | $0.05 | $1.47 | $1.47 | |
| Total assets | $11.51 | $15.78 | $30.39 | $33.96 |
| Current liabilities | ||||
| Accounts payable | $0.37 | $0.39 | $0.72 | $1.92 |
| Deferred revenue | $0.27 | $0.36 | $4.34 | |
| Short long term debt | $0.02 | $0.38 | $0.43 | |
| Total current liabilities | $0.59 | $2.47 | $3.14 | $3.91 |
| Long term debt | $8.23 | $8.33 | ||
| Total noncurrent liabilities | $8.23 | $12.05 | ||
| Total debt | $0.02 | $8.61 | $8.76 | |
| Total liabilities | $0.59 | $2.47 | $11.37 | $15.96 |
| Shareholders' equity | ||||
| Retained earnings | -$295.17 | -$292.58 | -$286.77 | -$287.6 |
| Other shareholder equity | -$0 | -$0 | -$0 | -$0 |
| Total shareholder equity | $13.31 | $19.02 | $18 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $19.17 | $35.78 | $53.84 | $31.66 |
| Short term investments | ||||
| Net receivables | $0.93 | $1.3 | $0.07 | $0.08 |
| Inventory | ||||
| Total current assets | $20.84 | $38.15 | $54.78 | $32.54 |
| Long term investments | $1.47 | $1.47 | $1.63 | $0.2 |
| Property, plant & equipment | $11.47 | $0.94 | $2.41 | $1.85 |
| Goodwill & intangible assets | $3.58 | |||
| Total noncurrent assets | $13.12 | $2.81 | $4.04 | $5.63 |
| Total investments | $1.47 | $1.47 | $1.63 | $0.2 |
| Total assets | $33.96 | $40.95 | $58.82 | $38.17 |
| Current liabilities | ||||
| Accounts payable | $1.92 | $1.19 | $0.84 | $0.93 |
| Deferred revenue | $4.34 | $6.16 | $7.01 | $10.33 |
| Short long term debt | $0.43 | $0.86 | $1.43 | $1.14 |
| Total current liabilities | $3.91 | $5.02 | $4.44 | $8.25 |
| Long term debt | $8.33 | $0.86 | $0.61 | |
| Total noncurrent liabilities | $12.05 | $4.82 | $6.93 | $6.78 |
| Total debt | $8.76 | $0.86 | $2.29 | $1.74 |
| Total liabilities | $15.96 | $9.84 | $11.37 | $15.03 |
| Shareholders' equity | ||||
| Retained earnings | -$287.6 | -$273.48 | -$254.64 | -$234.47 |
| Other shareholder equity | -$0 | -$0 | -$0 | |
| Total shareholder equity | $18 | $31.11 | $47.45 | $23.14 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.55 | $5.88 | $2.2 | |
| Cost of revenue | ||||
| Gross Profit | $1.55 | $5.88 | $2.2 | |
| Operating activities | ||||
| Research & development | $2.83 | $3.51 | $3.52 | |
| Selling, general & administrative | $2 | $1.63 | $0.91 | |
| Total operating expenses | $7.45 | $5.14 | $4.43 | |
| Operating income | -$5.9 | $0.75 | -$2.23 | |
| Income from continuing operations | ||||
| EBIT | -$5.81 | $0.82 | -$2.08 | |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$5.81 | $0.82 | -$2.08 | |
| Income (for common shares) | -$5.81 | $0.82 | -$2.08 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7.3 | $6.07 | $5.17 | $12.63 |
| Cost of revenue | ||||
| Gross Profit | $7.3 | $6.07 | $5.17 | $12.63 |
| Operating activities | ||||
| Research & development | $15.52 | $18.24 | $15.38 | $15.61 |
| Selling, general & administrative | $6.52 | $6.78 | $6.38 | $6.89 |
| Total operating expenses | $22.04 | $25.02 | $25.34 | $22.5 |
| Operating income | -$14.74 | -$18.95 | -$20.17 | -$9.86 |
| Income from continuing operations | ||||
| EBIT | -$14.12 | -$18.84 | -$20.17 | -$19.31 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$14.12 | -$18.84 | -$20.17 | -$19.31 |
| Income (for common shares) | -$14.12 | -$18.84 | -$23.37 | -$19.31 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$5.81 | $0.82 | -$2.08 | |
| Operating activities | ||||
| Depreciation | $0.16 | $0.27 | $0.21 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.1 | $0.2 | $0.2 | |
| Total cash flows from operations | -$3.68 | -$2.72 | -$2.01 | |
| Investing activities | ||||
| Capital expenditures | -$0.24 | -$0.15 | -$0.3 | |
| Investments | ||||
| Total cash flows from investing | -$0.4 | -$0.24 | -$0.15 | -$0.3 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | ||||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$9.85 | -$3.92 | -$2.87 | -$2.32 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$14.12 | -$18.84 | -$20.17 | -$19.31 |
| Operating activities | ||||
| Depreciation | $1.48 | $1.54 | $1.24 | $1.04 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.95 | $1.11 | $1.16 | $1.16 |
| Total cash flows from operations | -$15.98 | -$19.36 | -$19.73 | -$12.48 |
| Investing activities | ||||
| Capital expenditures | -$0.68 | -$0.09 | -$0.14 | -$0.28 |
| Investments | ||||
| Total cash flows from investing | -$0.68 | -$0.09 | -$0.14 | -$0.28 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.05 | $1.38 | $37.28 | $20.98 |
| Net borrowings | ||||
| Total cash flows from financing | $0.05 | $1.23 | $43.48 | $20.98 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$16.61 | -$18.21 | $23.6 | $8.22 |
News
|
Pulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Zacks via Yahoo Finance
11 Sep 2023
|
|
HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Lags Revenue Estimates
Zacks via Yahoo Finance
10 Aug 2023
|
|
Pulmatrix Says Formulated Inhaled Migraine Candidate Safe With Fewer GI Side Effects Compared To IV
Benzinga via Yahoo Finance
4 Jan 2023
|
|
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance
5 May 2022
|
|
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse...
Benzinga
25 Feb 2022
|
|
45 Stocks Moving In Friday's Mid-Day Session
Benzinga
25 Feb 2022
|
|
32 Stocks Moving in Friday's Pre-Market Session By Benzinga
Investing.com
25 Feb 2022
|
|
When Will Pulmatrix, Inc. (NASDAQ:PULM) Turn A Profit?
Simply Wall St. via Yahoo Finance
2 Feb 2022
|
|
20 Stocks Moving in Tuesday's Pre-Market Session
Benzinga
25 Jan 2022
|
|
Is TBLT Stock A Buy Here?
Insider Monkey via Yahoo Finance
7 Dec 2021
|
Fundamentals
| Market cap | $17.45M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 3.65M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.89 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 19.40 |
| Quick ratio | N/A |